Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Trial Profile

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs ZW 25 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Zymeworks
  • Most Recent Events

    • 06 Jun 2017 Results (n=9), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2017 Results from the dose escalation portion of this trial published in a Zymeworks media release.
    • 17 May 2017 Dr. Funda Meric-Bernstam is the lead investigator of this trial according to a Zymeworks media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top